Range-Bounded Adaptive Therapy in Metastatic Prostate Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Clinical Data
2.2. Mathematical Model
2.3. Conventional Adaptive and Range-Bounded Adaptive Therapy
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
- Gatenby, R.A.; Silva, A.S.; Gillies, R.J.; Frieden, B.R. Adaptive therapy. Cancer Res. 2009, 69, 4894–4903. [Google Scholar] [CrossRef] [Green Version]
- Zhang, J.; Cunningham, J.J.; Brown, J.S.; Gatenby, R.A. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat. Commun. 2017, 8, 1816. [Google Scholar] [CrossRef] [Green Version]
- Bruchovsky, N.; Klotz, L.; Crook, J.; Malone, S.; Ludgate, C.; Morris, W.J.; Gleave, M.E.; Goldenberg, S.L. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: Clinical parameters. Cancer 2006, 107, 389–395. [Google Scholar] [CrossRef]
- Zhang, J.; Fishman, M.N.; Brown, J.S.; Gatenby, R.A. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer (mCRPC): Updated analysis of the adaptive abiraterone (abi) study (NCT02415621). J. Clin. Oncol. 2019, 37, 5041. [Google Scholar] [CrossRef]
- Hansen, E.; Karslake, J.; Woods, R.J.; Read, A.F.; Wood, K.B. Antibiotics can be used to contain drug-resistant bacteria by maintaining sufficiently large sensitive populations. PLoS Biol. 2020, 18, e3000713. [Google Scholar] [CrossRef]
- Kim, E.; Brown, J.S.; Eroglu, Z.; Anderson, A.R.A. Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models. Cancers 2021, 13, 823. [Google Scholar] [CrossRef]
- Enriquez-Navas, P.M.; Kam, Y.; Das, T.; Hassan, S.; Silva, A.; Foroutan, P.; Ruiz, E.; Martinez, G.; Minton, S.; Gillies, R.J.; et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci. Transl. Med. 2016, 8, 327ra324. [Google Scholar] [CrossRef] [Green Version]
- Silva, A.S.; Kam, Y.; Khin, Z.P.; Minton, S.E.; Gillies, R.J.; Gatenby, R.A. Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res. 2012, 72, 6362–6370. [Google Scholar] [CrossRef] [Green Version]
- Crook, J.M.; O’Callaghan, C.J.; Duncan, G.; Dearnaley, D.P.; Higano, C.S.; Horwitz, E.M.; Frymire, E.; Malone, S.; Chin, J.; Nabid, A.; et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N. Engl. J. Med. 2012, 367, 895–903. [Google Scholar] [CrossRef]
- Wargo, A.R.; Huijben, S.; de Roode, J.C.; Shepherd, J.; Read, A.F. Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc. Natl. Acad. Sci. USA 2007, 104, 19914–19919. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nakazawa, M.; Paller, C.; Kyprianou, N. Mechanisms of Therapeutic Resistance in Prostate Cancer. Curr. Oncol. Rep. 2017, 19, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hansen, E.; Read, A.F. Modifying Adaptive Therapy to Enhance Competitive Suppression. Cancers 2020, 12, 3556. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Cunningham, J.; Brown, J.; Gatenby, R. Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes. eLife 2022, 11, e76284. [Google Scholar] [CrossRef] [PubMed]
- Brady-Nicholls, R.; Nagy, J.D.; Gerke, T.A.; Zhang, T.; Wang, A.Z.; Zhang, J.; Gatenby, R.A.; Enderling, H. Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation. Nat. Commun. 2020, 11, 1750. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brady-Nicholls, R.; Zhang, J.; Zhang, T.; Wang, A.Z.; Butler, R.; Gatenby, R.A.; Enderling, H. Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics. Neoplasia 2021, 23, 851–858. [Google Scholar] [CrossRef]
- Gallaher, J.A.; Enriquez-Navas, P.M.; Luddy, K.A.; Gatenby, R.A.; Anderson, A.R.A. Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies. Cancer Res. 2018, 78, 2127–2139. [Google Scholar] [CrossRef] [Green Version]
- Strobl, M.A.R.; West, J.; Viossat, Y.; Damaghi, M.; Robertson-Tessi, M.; Brown, J.S.; Gatenby, R.A.; Maini, P.K.; Anderson, A.R.A. Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy. Cancer Res. 2021, 81, 1135–1147. [Google Scholar] [CrossRef]
- Viossat, Y.; Noble, R. A theoretical analysis of tumour containment. Nat. Ecol. Evol. 2021, 5, 826–835. [Google Scholar] [CrossRef]
- West, J.; Ma, Y.; Newton, P.K. Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment. J. Theor. Biol. 2018, 455, 249–260. [Google Scholar] [CrossRef]
- Brady, R.; Enderling, H. Mathematical Models of Cancer: When to Predict Novel Therapies, and When Not to. Bull. Math. Biol. 2019, 81, 3722–3731. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pasetto, S.; Enderling, H.; Gatenby, R.A.; Brady-Nicholls, R. Intermittent Hormone Therapy Models Analysis and Bayesian Model Comparison for Prostate Cancer. Bull. Math. Biol. 2021, 84, 2. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Brady-Nicholls, R.; Enderling, H. Range-Bounded Adaptive Therapy in Metastatic Prostate Cancer. Cancers 2022, 14, 5319. https://doi.org/10.3390/cancers14215319
Brady-Nicholls R, Enderling H. Range-Bounded Adaptive Therapy in Metastatic Prostate Cancer. Cancers. 2022; 14(21):5319. https://doi.org/10.3390/cancers14215319
Chicago/Turabian StyleBrady-Nicholls, Renee, and Heiko Enderling. 2022. "Range-Bounded Adaptive Therapy in Metastatic Prostate Cancer" Cancers 14, no. 21: 5319. https://doi.org/10.3390/cancers14215319